Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04486833
Title Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib (Acclaim-1)
Acronym Acclaim-1
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Genprex, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Valkyrie Clinical Trials RECRUITING Los Angeles California 90067 United States Details
Rocky Mountain Cancer Centers RECRUITING Lone Tree Colorado 80124 United States Details
Carle Cancer Institute RECRUITING Urbana Illinois 61801 United States Details
Maryland Oncology Hematology RECRUITING Rockville Maryland 20850 United States Details
The Valley Hospital - Luckow Pavilion RECRUITING Paramus New Jersey 07652 United States Details
Millennium Oncology RECRUITING Houston Texas 77090 United States Details
Virginia Cancer Specialists RECRUITING Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field